Schwartz Biomedical

News


Latest News

Orthopaedic Company, BioPoly LLC, Announces Issuance of Patent

Posted: Feb 18th, 2010
FORT WAYNE, IN — BioPoly LLC, a local orthopaedic device manufacturer and Schwartz Biomedical subsidiary, announces that one of its key patents has issued. The issuance of this patent protects the BioPoly™ material claims and provides the company with a unique competitive advantage. This patent is one of an entire family of patents that have been filed to protect this technology. BioPoly LLC obtained an exclusive license for this technology from Colorado State University.

The BioPoly™ material is being used by the company in a host of orthopaedic implant applications. The unique characteristics of the BioPoly™ material allow it to interface optimally with orthopaedic tissues; thus, allowing direct contact between BioPoly™ and cartilage and/or bone. The first product being released to the market takes advantage of this attribute by the partial resurfacing of the knee joint; therefore, only the damaged portion of the knee surface is replaced, leaving the remaining healthy tissue intact.

According to the company’s Chief Financial Officer, Sabra Rowley CPA, “The issuance of this patent supports the investments made into this technology. We are excited to be able to offer the forthcoming implants to patients soon.”


About Schwartz Biomedical
Schwartz Biomedical is a tissue engineering company located in Fort Wayne, Indiana. With its engineers and scientists, the company innovates, researches, and develops novel tissue engineering and biologically based solutions to orthopaedic problems. Web site: www.schwartzbiomedical.com

About BioPoly
BioPoly LLC is an orthopaedic research, design and manufacturing company also located in Fort Wayne, Indiana. The company is developing and manufacturing products for use in the sports medicine, orthopaedics, and spinal markets.

BioPoly™ Raises $2M for Commercialization of Orthopaedic Products

Posted: Jan 12th, 2010
FORT WAYNE, IN — BioPoly LLC, a Schwartz Biomedical subsidiary, has raised more than $2M in its first round of equity financing. This capital will be used to complete product development and initiate launch of its first orthopaedic products into the market.

Although, this capital represents the first round of equity financing, initial support for this venture was provided by nearly $4M from two Indiana 21 Fund grants and other internal funding sources. The BioPoly™ team along with the collaborative efforts of Colorado State University and the Northeast Indiana Innovation Center has been developing a family of orthopaedic products. According to Dr. Herb Schwartz, President and CEO, “the unique patent-protected BioPoly™ technology allows us to apply very innovative solutions to orthopaedic problems.” One of the implant applications that is being developed includes using the BioPoly™ material as a synthetic cartilage for partial resurfacing of the knee. By partially resurfacing, the surgeon can replace the defective cartilage instead of the entire joint (total joint reconstruction) or even half of the joint (uni-knee), thus, allowing the patient to retain more of his/her native tissue.

Dr. Janine Campbell, Director of Science and Regulatory Affairs, stated that “the BioPoly™ material’s hydrophilic (water attracting) nature along with robust mechanical properties provides implants that optimally interface with orthopaedic tissues.” The combination of the hydrophilic characteristics and mechanical strength is accomplished via a proprietary method of incorporating two very dissimilar materials: a well-known orthopaedic polymer and a naturally occurring lubricating molecule known as a polysaccharide. The BioPoly™ material is essentially a self-lubricating orthopaedic plastic material that behaves much like the cartilage it is replacing.

In addition to partial resurfacing, the BioPoly™ team is also developing many other applications for use in orthopaedics, sports medicine, and spinal applications. “We and our investors are very excited to be able to introduce this technology to the orthopaedic industry,” said Schwartz. The first product is expected to launch very soon.


About Schwartz Biomedical:
Schwartz Biomedical is a tissue engineering company located in Fort Wayne, Indiana. With its engineers and scientists, the company innovates, researches, and develops novel tissue engineering and biologically based solutions to orthopaedic problems. Web site: www.schwartzbiomedical.com

About BioPoly:
BioPoly LLC is an orthopaedic research, design and manufacturing company also located in Fort Wayne, Indiana. The company is developing and manufacturing products for use in the sports medicine, orthopaedics, and spinal markets.

Fort Wayne Orthopaedic Company Receives Technology Funding

Posted: May 01st, 2007
FORT WAYNE, IN — Schwartz Biomedical subsidiary, BioPoly LLC, has been awarded $2MM from Indiana’s 21st Century Fund to develop a new orthopaedic implant, called BioPoly™ RS (ReSurfacing), which will be used to replace only the damaged portion of a joint (i.e. knee, hip, shoulder, phalanges, etc…) as opposed to the entire joint. Patients receiving this new implant will not have to put up with chronic pain that many arthritis sufferers endure while they wait for their joint to deteriorate to the point where they are total joint replacement candidates.

According to Herb Schwartz Ph.D., President and CEO of Schwartz Biomedical LLC and BioPoly RS LLC, the grant will enable Schwartz Biomedical to complete its preclinical research and product development work, as well as the FDA submission which will allow the product to be sold as a medical device. “Our timeline is aggressive,” according to Schwartz, “Product development should be complete within the next 2-3 years with the first implant ready for market launch in 2009.” In order to accomplish this goal, Janine Campbell Ph.D., a Principal Scientist who specializes in chemistry, has joined the Schwartz Biomedical team and will provide her expertise toward the commercialization of this technology.

Schwartz Biomedical has partnered with Colorado State University and the Northeast Indiana Innovation Center to complete the development and commercialization of the BioPoly™ RS implant technology.

The BioPoly™ RS material platform is a hydrophilic polymer which has mechanical and biochemical properties similar to that of native articular cartilage so that the implant can interface and articulate with normal joint tissue. Therefore, if the patient has a focal cartilage defect, the surgeon will have a viable option of replacing, or partially resurfacing, only the damaged tissue with the BioPoly™ RS implant such that the implant will physiologically share the biomechanical loads.

In 2004, Schwartz Biomedical received its first grant, totaling $1.27 million, from the state's 21st Century Research to commercialize a new total joint material. In 2005, one of Schwartz Biomedical’s subsidiary companies (BioDuct LLC) received $1.35 million in investment capital to complete product development work for a tissue regeneration technology for the knee.

About Schwartz Biomedical

Schwartz Biomedical is a tissue engineering company located in the Northeast Indiana Innovation Center in Fort Wayne, Indiana. With its engineers and scientists, the company innovates and develops novel tissue engineering solutions for orthopaedic problems. Web site: www.schwartzbiomedical.com

Prior to founding his own company, Dr. Schwartz was employed by one of the major orthopaedic manufacturers of Warsaw, Indiana in their Orthobiologics (tissue engineering) Department. While there, Dr. Schwartz established himself as a prolific innovator and has generated more than 30 U.S. patents (issued or pending) in the field of orthopaedics and tissue engineering. He received his Ph.D. and MS in Biomechanical Engineering from the University of Cincinnati and his BS in Mechanical Engineering from Purdue University.

source: http://www.insideindianabusiness.com/newsitem.asp?id=20338